A rapid and efficient single-cell manipulation method for screening antigen-specific antibody–secreting cells from human peripheral blood

Aishun Jin1,2,6, Tatsuhiko Ozawa1,6, Kazuto Tajiri1,3,6, Tsutomu Obata4, Sachiko Kondo1, Koshi Kinoshita1, Shinichi Kadowaki1, Kazuo Takahashi3, Toshiro Sugiyama3, Hiroyuki Kishi1 & Atsushi Muraguchi1

Antigen-specific human monoclonal antibodies (mAbs) are key candidates for therapeutic agents. However, the availability of a suitable screening system for antigen-specific antibody–secreting cells (ASCs) is limited in humans. Here we present a unique method for detecting individual ASCs using microwell array chips, which enables the analysis of live cells on a single-cell basis and offers a rapid, efficient and high-throughput (up to 234,000 individual cells) system for identifying and recovering objective ASCs. We applied the system to detect and retrieve ASCs for hepatitis B virus and influenza viruses from human peripheral blood lymphocytes and produced human mAbs with virus-neutralizing activities within a week. Furthermore, we show that the system is useful for detecting ASCs for multiple antigens as well as for selection of ASCs secreting high-affinity antibodies on a chip. Our method can open the way for the generation of therapeutic antibodies for individual patients.

Pandemic outbreaks of infections, such as that of the severe acute respiratory syndrome in 2003 and influenza in 1918, have caused high mortality. Vaccines are effective for preventing infectious diseases. However, it takes a long time to develop and produce them. Antibody therapeutics is another method used for prevention and therapy for newly emerging viruses. A rapid and efficient method of selecting and producing objective antibodies is required for preventing a pandemic outbreak of an infection. A principal concern in developing antibody therapeutics is the immunogenicity of mAbs in patients.

To overcome this problem, various procedures for obtaining fully human antibodies have been developed, including phage display libraries of artificial antibody fragments of human origin2–4. Other methods select antibodies that are naturally produced in humans. Attempts have been made to establish hybridomas producing human mAbs5 or Epstein-Barr virus–immortalized human ASCs6–8. Furthermore, protocols for isolating antibody heavy and light chain variable region (\(V_H\) and \(V_L\)) complementary DNA pairs by RT-PCR directly from single B lineage cells have also been designed9–11. Although feasible, these systems are limited by the throughput for the selection of antigen-specific B cells.

Previously, we proposed a cell-based microarray system for developing antigen-specific human mAbs directly from human peripheral blood lymphocytes (PBLs)12–14. In this study, we tried to establish a rapid and efficient method for obtaining antigen-specific antibodies using a cell-based microarray system, which detects the secretion of antibodies with desired specificity from single cells in a large population of primary lymphocytes.

RESULTS

Detection of antigen-specific ASCs on a chip

We prepared an array of single live cells by applying ASCs to a microarray chip (Fig. 1a). The chip surface was coated with antibodies against immunoglobulin, and the antibodies secreted by an ASC were trapped on the surface around the well. Binding of the antigen to the specific antibodies formed distinct circular spots, which were easily distinguishable from nonspecific signals. We then retrieved the detected antigen-specific ASCs, recovered antibody cDNA, and produced antibodies within a week15. We named this method ‘immunospot array assay on a chip’ (ISAAC).

First, we tested the feasibility of ISAAC for detecting ASCs on a single-cell basis using the 110TC, HyHEL10/110TC and HB0116/X63 cell lines, which produce no antibodies, antibody to hen egg lysozyme (HEL) and antibody to hepatitis B virus surface antigen (HBs antigen), respectively (Fig. 1b). We cultured the cells on a chip for 3 h and detected the secreted antibodies with biotinylated antigens (HEL or HBs antigen) and Cy3 conjugates of streptavidin (Cy3-streptavidin). We observed signals from the secreted antibodies outside of wells that contained either HyHEL10/110TC or HB0116/X63 cells, but not outside of wells containing 110TC cells (Fig. 1b). Labeled HEL did not detect HBs antigen–specific ASCs, and labeled HBs

1Department of Immunology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan. 2SC World Inc., Toyama, Japan. 3The Third Department of Internal Medicine, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan. 4Central Research Institute, Toyama Industrial Technology Center, Takaoka, Toyama, Japan. 5Department of Infectious Diseases, Osaka Prefectural Institute of Public Health, Osaka, Japan. 6These authors contributed equally to this work. Correspondence should be addressed to H.K. (immkishi@med.u-toyama.ac.jp).

Received 17 February; accepted 16 April; published online 16 August 2009; doi:10.1038/nm.1966
antigen did not detect HEL-specific ASCs (data not shown). To identify the cells, we stained them on the chips with Oregon Green. Not all of the cells secreted antibodies (more than 15%); Fig. 1b). The results corresponded with those of an ELISPOT assay, which showed that about 10% of the cells secreted antibodies (data not shown). These results indicate that the ISAAC detects ASCs at the single-cell level in culture within only a 3-h period and in an antigen-specific manner, implying the high specificity and speed of the method.

Figure 2 Detection of virus-specific ASCs derived from human peripheral blood of HBs antigen– or influenza virus–vaccinated volunteers by ISAAC. (a) Detection of HBs antigen–specific ASCs. ASCs were detected using HEL (top left, negative control) or HBs antigen (top middle). The cells were then stained with Oregon Green, and the antibody signals (top) and cell signals were merged (bottom). Expanded views are shown for the region marked with yellow boxes (right). The arrowhead indicates the HBs antigen–specific ASC. (b) Antigen specificity of the antibodies derived from single ASCs using ISAAC, as examined by competitive ELISA using varying amounts of HBs antigen. Data represent means ± s.d. (c) Antigen specificities of the antibodies derived from single ASCs using ISAAC, as examined by competitive ELISA using varying doses of influenza virus type B. Data represent means ± s.d. (d) Correlation of 34 independent HBs antigen–specific antibody clones derived from a volunteer. The antibodies in groups I–IV showed similar amino acid sequences in each group. The antibodies in groups V–VIII showed identical amino acid sequences in each group. The rest of the clones showed unrelated amino acid sequences. (e) Correlation of 19 independent InV-specific antibody clones. The antibodies in groups I–III showed corresponding amino acid sequences in each group. The antibodies in group IV showed identical amino acid sequences. The rest of the clones showed unrelated amino acid sequences.
Characterization of influenza-specific antibodies

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Affinity, $K_d$ (M)$^a$</th>
<th>Epitope$^b$</th>
<th>Neutralization activity$^c$</th>
<th>Antibody</th>
<th>Affinity, $K_d$ (M)</th>
<th>Epitope</th>
<th>Neutralization activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>HB0116</td>
<td>$3.63 \times 10^{-9}$</td>
<td>2</td>
<td>++</td>
<td>HB4-38</td>
<td>$1.22 \times 10^{-7}$</td>
<td>2</td>
<td>++</td>
</tr>
<tr>
<td>HB0477</td>
<td>$2.69 \times 10^{-7}$</td>
<td>1</td>
<td>−</td>
<td>HB4-40</td>
<td>$1.07 \times 10^{-9}$</td>
<td>3</td>
<td>+</td>
</tr>
<tr>
<td>HB0478</td>
<td>$2.91 \times 10^{-7}$</td>
<td>2</td>
<td>++</td>
<td>HB4-42</td>
<td>$3.57 \times 10^{-10}$</td>
<td>3</td>
<td>+</td>
</tr>
<tr>
<td>HB0905</td>
<td>$2.03 \times 10^{-8}$</td>
<td>2</td>
<td>+</td>
<td>HB4-44</td>
<td>$3.11 \times 10^{-7}$</td>
<td>3</td>
<td>+</td>
</tr>
<tr>
<td>HB1089</td>
<td>$2.77 \times 10^{-8}$</td>
<td>2</td>
<td>+</td>
<td>HB4-48</td>
<td>$5.53 \times 10^{-8}$</td>
<td>2</td>
<td>ND</td>
</tr>
<tr>
<td>HB3-63</td>
<td>$1.22 \times 10^{-9}$</td>
<td>2</td>
<td>−</td>
<td>HB5-53</td>
<td>$8.03 \times 10^{-7}$</td>
<td>3</td>
<td>+/−</td>
</tr>
<tr>
<td>HB3-67</td>
<td>$3.03 \times 10^{-8}$</td>
<td>ND</td>
<td>−</td>
<td>HB6-60</td>
<td>$6.30 \times 10^{-8}$</td>
<td>3</td>
<td>+/−</td>
</tr>
<tr>
<td>HB3-68</td>
<td>$2.93 \times 10^{-6}$</td>
<td>2</td>
<td>−</td>
<td>HB6-62</td>
<td>$6.20 \times 10^{-8}$</td>
<td>4</td>
<td>−</td>
</tr>
<tr>
<td>HB3-70</td>
<td>$1.94 \times 10^{-10}$</td>
<td>4</td>
<td>−</td>
<td>HB6-65</td>
<td>$5.36 \times 10^{-8}$</td>
<td>3</td>
<td>−</td>
</tr>
<tr>
<td>HB3-78</td>
<td>$1.82 \times 10^{-9}$</td>
<td>4</td>
<td>−</td>
<td>HB4-74</td>
<td>$6.53 \times 10^{-9}$</td>
<td>4</td>
<td>−</td>
</tr>
<tr>
<td>HB3-81</td>
<td>$3.59 \times 10^{-6}$</td>
<td>4</td>
<td>−</td>
<td>HB5-17</td>
<td>$6.75 \times 10^{-8}$</td>
<td>1</td>
<td>++</td>
</tr>
<tr>
<td>HB4-21</td>
<td>$2.39 \times 10^{-7}$</td>
<td>ND</td>
<td>−</td>
<td>HB5-18</td>
<td>$1.87 \times 10^{-7}$</td>
<td>3</td>
<td>+/−</td>
</tr>
<tr>
<td>HB4-22</td>
<td>$7.25 \times 10^{-8}$</td>
<td>2</td>
<td>++</td>
<td>HB5-21</td>
<td>$2.07 \times 10^{-7}$</td>
<td>4</td>
<td>++</td>
</tr>
<tr>
<td>HB4-25</td>
<td>$1.03 \times 10^{-7}$</td>
<td>2</td>
<td>+</td>
<td>HB5-23</td>
<td>$2.07 \times 10^{-7}$</td>
<td>4</td>
<td>++</td>
</tr>
<tr>
<td>HB4-31</td>
<td>$5.26 \times 10^{-7}$</td>
<td>2</td>
<td>+/−</td>
<td>HB5-88</td>
<td>$1.10 \times 10^{-7}$</td>
<td>4</td>
<td>++</td>
</tr>
<tr>
<td>HB4-34</td>
<td>$1.07 \times 10^{-7}$</td>
<td>ND</td>
<td>+</td>
<td>HB5-98</td>
<td>$5.24 \times 10^{-7}$</td>
<td>4</td>
<td>++</td>
</tr>
</tbody>
</table>

$^a$Affinities were analyzed with surface plasmon resonance analysis. $^b$Epitopes were examined by ELISA using synthesized polypeptides (1, amino acids 104–120; 2, amino acids 121–137; 3, amino acids 139–148; 4, amino acids 149–163) of the extracellular domain of HBs antigen. $^c$Neutralization activity: ++, more than 60% inhibition; +, 40%–60% inhibition; +/−, 20%–40% inhibition (as compared with data using control IgG).

We then verified whether ISAAC can efficiently detect antigen-specific ASCs in lymphoid tissues using HEL-immunized mice. We arrayed CD138$^+$ plasma cells on a chip and detected HEL-specific ASCs using labeled HEL. We observed strong signals of HEL that bound the secreted antibodies on the chip (Fig. 1c and Supplementary Fig. 1). The signals were specific, as we did not observe any spots with labeled HBs antigen as a negative control (Fig. 1c). We did not detect HEL-specific signals when we analyzed CD138$^+$ cells from unimmunized mice (data not shown). When we analyzed approximately 10,000 cells, ISAAC detected an average of 27 spots of HEL-bound IgG (Supplementary Table 1). We simultaneously performed an ELISPOT assay with the same cell preparations. We found that the number of HEL-specific ASCs detected by ISAAC is about four times higher than that detected by ELISPOT assay (Fig. 1d). The results show that ISAAC can detect antigen-specific ASCs in primary lymphocytes at the single-cell level with high efficiency and sensitivity.

### Table 2 Characterization of influenza-specific antibodies

<table>
<thead>
<tr>
<th>Antibody</th>
<th>H1N1</th>
<th>H3N2</th>
<th>H5N1</th>
<th>B</th>
</tr>
</thead>
<tbody>
<tr>
<td>InV-03</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>InV-07</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>+</td>
</tr>
<tr>
<td>InV-10</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>InV-15</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>+</td>
</tr>
<tr>
<td>InV-16</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>InV-17</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>InV-19</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>+</td>
</tr>
<tr>
<td>InV-22</td>
<td>−</td>
<td>−</td>
<td>−</td>
<td>+</td>
</tr>
<tr>
<td>InV-32</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>InV-33</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>InV-34</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>InV-43</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>InV-47</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>InV-49</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>InV-50</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>InV-58</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>InV-61</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

$^a$Affinity was analyzed with surface plasmon resonance analysis. $^b$Neutralization activity is the antibody concentration required for $\text{neutralization}$ of A/New Caledonia/20/99 strain and B/Malaysia/2506/2004 strain using Madin-Darby canine kidney (MDCK) cells.

We then attempted to determine whether ISAAC can be used to obtain antigen-specific human mAbs directly from human peripheral blood B cells.
We vaccinated healthy volunteers with HBs vaccine (yeast-derived recombinant HBs antigen) and prepared CD138+ plasma cells from PBLs on day 7 after the boost. The cells were arrayed on a chip coated with antibodies to human IgG. We specifically detected secreted antibodies to HBs antigen with labeled HBs antigen, but not with labeled HEL (Fig. 2a and Supplementary Fig. 2). We detected HBs antigen–specific ASCs at a frequency of 0.17% on day 7 after the boost. Before the boost with HBs antigen, HBs antigen–specific ASCs were barely detectable (data not shown). We retrieved 104 single detected cells and amplified antibody cDNAs. We amplified 68 pairs of antibody V<sub>H</sub> and V<sub>L</sub> cDNAs, inserted them into expression vectors and transfected them into Chinese hamster ovary (CHO) cells. ELISA and competitive binding assay showed that 45 of the pairs of antibody cDNAs yielded antibodies specific to HBs antigen (Fig. 2b and Supplementary Table 1).

We also produced influenza virus–specific antibodies directly from CD138<sup>+</sup> cells in the human peripheral blood of influenza-vaccinated volunteers. We detected influenza virus–specific ASCs at a frequency of 0.69% on day 10 after the boost. We amplified 46 pairs of antibody V<sub>H</sub> and V<sub>L</sub> cDNAs from 63 retrieved cells. ELISA and competitive binding assay showed that 19 antibodies specifically bound the virus (Fig. 2c and Supplementary Table 1). In these experiments, not all of the produced antibodies bound the antigens. This might be due to the retrieval of unnecessary cells together with the objective cell and amplification of cDNAs from nonspecific antibody–producing cells, leading to the production of nonspecific antibodies. Especially in the influenza experiments, we observed nonspecific binding of CD138<sup>+</sup> cells on the chip surface, which resulted in our retrieving more than two cells.

Characterization of virus-specific human antibodies

We analyzed the affinities and neutralization activities of HBs antigen–specific or influenza virus–specific antibodies (Tables 1 and 2). The affinities, analyzed with surface plasmon resonance, ranged from $1 \times 10^{-6}$ to $1 \times 10^{-10}$ M for HBs antigen–specific antibodies and from $1 \times 10^{-9}$ to $1 \times 10^{-5}$ M for influenza hemagglutinin–specific antibodies. When we analyzed inhibitory activities of antibodies for virus infection in vitro, half of the HBs antigen–specific antibodies and all of the hemagglutinin–specific antibodies inhibited the virus infection (Tables 1 and 2). We did not observe substantial correlation between their affinities and inhibitory activities. Notably, we obtained one influenza virus–specific antibody for the extracellular domain of matrix protein 2 (M2e)<sup>16,17</sup>, which reacted to various types of influenza viruses, including H5N1 (Table 2). It is well known that infection with the hepatitis B virus still threatens health across the world, notwithstanding the development of vaccines, and that a pandemic outbreak of H5N1 influenza virus infection is a major concern. Thus, ISAAC could very efficiently contribute to the supply of virus-neutralizing antibodies by detecting antigen–specific ASCs from primary lymphocytes in human peripheral blood and producing human mAbs very rapidly.

When we analyzed the cDNA sequences of HBs antigen– and influenza virus–specific antibodies that we obtained from ASCs in an individual with ISAAC, we could categorize them into several groups with similar sequences, identical sequences and completely distinct sequences (Fig. 2d,e and Supplementary Fig. 3). These results suggest that ISAAC can identify ASC clones whose antibodies are diversified through antigen–driven differentiation or expansion of memory B cells during immune responses. Another group of researchers has reported the pauciclonal expansion of influenza–specific B cells and repertoire diversification with somatic hypermutation after booster vaccination.<sup>18</sup> Thus, ISAAC could also be useful for lymphocyte repertoire analysis.

Additional applications of ISAAC

We next examined whether ISAAC could detect ASCs to distinct antigens on a chip by using multiple antigens with different fluorophores. We could detect cells secreting HBs antigen–specific antibodies and those secreting HEL–specific antibodies with FITC conjugated to HBs antigen and biotinylated HEL and Cy3–streptavidin, respectively (Fig. 3a). Recently, the number of fluorophores that can be used in microscopy and cytometry has been increasing, which enabled us to detect ASCs for multiple antigens on a chip.

We also produced influenza virus–specific antibodies directly from CD138<sup>+</sup> cells in the human peripheral blood of influenza-vaccinated volunteers. We detected influenza virus–specific ASCs at a frequency of 0.69% on day 10 after the boost. We amplified 46 pairs of antibody V<sub>H</sub> and V<sub>L</sub> cDNAs from 63 retrieved cells. ELISA and competitive binding assay showed that 19 antibodies specifically bound the virus (Fig. 2c and Supplementary Table 1). In these experiments, not all of the produced antibodies bound the antigens. This might be due to the retrieval of unnecessary cells together with the objective cell and amplification of cDNAs from nonspecific antibody–producing cells, leading to the production of nonspecific antibodies. Especially in the influenza experiments, we observed nonspecific binding of CD138<sup>+</sup> cells on the chip surface, which resulted in our retrieving more than two cells.

Characterization of virus-specific human antibodies

We analyzed the affinities and neutralization activities of HBs antigen–specific or influenza virus–specific antibodies (Tables 1 and 2). The affinities, analyzed with surface plasmon resonance, ranged from $1 \times 10^{-6}$ to $1 \times 10^{-10}$ M for HBs antigen–specific antibodies and from $1 \times 10^{-9}$ to $1 \times 10^{-5}$ M for influenza hemagglutinin–specific antibodies. When we analyzed inhibitory activities of antibodies for virus infection in vitro, half of the HBs antigen–specific antibodies and all of the hemagglutinin–specific antibodies inhibited the virus infection (Tables 1 and 2). We did not observe substantial correlation between their affinities and inhibitory activities. Notably, we obtained one influenza virus–specific antibody for the extracellular domain of matrix protein 2 (M2e)<sup>16,17</sup>, which reacted to various types of influenza viruses, including H5N1 (Table 2). It is well known that infection with the hepatitis B virus still threatens health across the world, notwithstanding the development of vaccines, and that a pandemic outbreak of H5N1 influenza virus infection is a major concern. Thus, ISAAC could very efficiently contribute to the supply of virus-neutralizing antibodies by detecting antigen–specific ASCs from primary lymphocytes in human peripheral blood and producing human mAbs very rapidly.

When we analyzed the cDNA sequences of HBs antigen– and influenza virus–specific antibodies that we obtained from ASCs in an individual with ISAAC, we could categorize them into several groups with similar sequences, identical sequences and completely distinct sequences (Fig. 2d,e and Supplementary Fig. 3). These results suggest that ISAAC can identify ASC clones whose antibodies are diversified through antigen–driven differentiation or expansion of memory B cells during immune responses. Another group of researchers has reported the pauciclonal expansion of influenza–specific B cells and repertoire diversification with somatic hypermutation after booster vaccination.<sup>18</sup> Thus, ISAAC could also be useful for lymphocyte repertoire analysis.

Additional applications of ISAAC

We next examined whether ISAAC could detect ASCs to distinct antigens on a chip by using multiple antigens with different fluorophores. We could detect cells secreting HBs antigen–specific antibodies and those secreting HEL–specific antibodies with FITC conjugated to HBs antigen and biotinylated HEL and Cy3–streptavidin, respectively (Fig. 3a). Recently, the number of fluorophores that can be used in microscopy and cytometry has been increasing, which enabled us to detect ASCs for multiple antigens on a chip.

Selection of antigen–specific antibodies with high affinity is one of the goals for the screening of mAbs. Thus, we investigated the possibility of selecting high-affinity ASCs with ISAAC (Fig. 3b,c). We individually cultured cells secreting antibodies with various dissociation constants ($K_d$) on the chips. We then detected the amount of secreted antibodies with FITC–conjugated antibody to human IgG and the amount of HBs antigen that bound the secreted antibodies with biotinylated HBs antigen and Cy3–streptavidin. When we calculated the ratio of the amount of bound antigens to the amount of secreted antibodies, the ratio was high for signals for high-affinity antibodies and low for low-affinity antibodies (Supplementary Methods). These results indicate that ISAAC enables direct screening and production of antigen–specific antibodies with high affinity. The representative ISAAC signals for secreted IgG and HBs antigen binding to secreted antibodies (HB0116, $K_d$ $3.63 \times 10^{-9}$ M and HB3–68, $K_d$ $2.93 \times 10^{-6}$ M) are shown in b. The ratios of Cy3 to FITC intensity (y-axis) and $K_d$ (x-axis) for each of six CHO cells secreting antibodies with different affinity were plotted in c. More than twenty ISAAC spots with the same affinity were examined. Data represent means ± s.e.m.
primary lymphocytes. Second, early segregation of cells during screening reduces the time and labor required to maintain many individual clones while characterizing the produced antibodies for appropriate reactivity in the immunochemical assays. Third, the ease of carrying and handling the chip allows for analysis of pathogen-specific ASCs on the spot of an infection outbreak and for a rapid response to the outbreak. Fourth, the 5′-rapid amplification of cDNA ends (5′-RACE) procedure\textsuperscript{19} is combined with ISAAC to produce an antigen-specific antibody, which enables the augmentation of antibody cDNA without the need to design 5′ V\textsubscript{H} primers. Fifth, ISAAC enables detection of multiple antigens and selection of ASCs secreting high-affinity antibodies on a chip.

Recently, another group reported a microengraving method for the selection of ASCs using an array of wells 50 μm (or 100 μm) in diameter and depth\textsuperscript{20}. Fundamentally, their method is based on ELISA, whereas our ISAAC is based on ELISPOT. In their procedure, they need to prepare the appropriate cell dilution for analyzing ASCs at single-cell levels. Furthermore, constant secretion of large amounts of antibody might be required to reach a sufficient concentration of antibody for detection because of the large well volume of their system. In these contexts, ISAAC seems to offer the more suitable, rapid and efficient protocol for detecting primary ASCs, although the microengraving protocol also enables their detection.

Regarding the frequencies of influenza-specific ASCs in PBL, another study recently reported about 2,500 influenza-specific IgG-secreting cells in a million PBLs from influenza-vaccinated subjects for the highest responder and about 100 influenza-specific IgG-secreting cells in a million PBLs from influenza-vaccinated subjects for the more suitable, rapid and efficient protocol for detecting primary ASCs, although the microengraving protocol also enables their detection.

In conclusion, ISAAC is applicable for analyzing and isolating ASCs with the desired specificity directly from human PBLs with very high efficiency and accuracy. ISAAC enables us to obtain antigen-specific mAbs within a week. The generation of human mAbs with high affinity from peripheral blood would be markedly enhanced by our method compared with conventional methods\textsuperscript{8,10,11}. ISAAC would be useful for the rapid generation of neutralizing antibodies in a pandemic outbreak of infectious diseases and would contribute to the antibody therapeutics for individual patients in the future.

METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.

Note: Supplementary information is available on the Nature Medicine website.

ACKNOWLEDGMENTS
We thank S. Hirota for technical assistance and K. Hata for secretarial work. We are very grateful to M. Isobe and N. Kurosawa, Laboratory of Molecular and Cellular Biology, Graduate School of Science and Engineering, University of Toyama, for their generous supply of an antibody expression system. We thank H. von Boehmer, Dana-Farber Cancer Institute, Harvard Medical School, for 110T cells. This research was supported by grants from the Toyama Medical Bio-Cluster Project and a Grant-in-Aid of the Ministry of Education, Culture, Sports, Science and Technology, Japan. A.J., K.K. and S. Kadowaki were supported by a postdoctoral fellowship from the Toyama Medical Bio-Cluster Project.

AUTHOR CONTRIBUTIONS
A.J. established the ISAAC protocol; T. Ozawa analyzed influenza-specific antibodies; K. Tajiri analyzed HBs antigen-specific antibodies; T. Obata developed microwell array chip for ISAAC; S. Kondo and K.K. constructed antibody expression vectors; S. Kadowaki analyzed cells; K. Takahashi analyzed influenza virus neutralization activity; T.S. supervised the project; and H.K. and A.M. organized and conducted the project.

COMPETING INTERESTS STATEMENT
The authors declare competing financial interests: details accompany the full-text HTML version of the paper at http://www.nature.com/naturemedicine/.

Published online at http://www.nature.com/naturemedicine/. Reprints and permissions information is available online at http://rnp.nature.com/reprintsandpermissions/.

Rapid focus reduction neutralization test of influenza A and B

We coated 96-well filter plates with biotinylated antibodies (M2e peptide [MSLITEVETPIRNEWGRCNDSSDK-biotin, Operon Biotechnologies] and polyepitopes of the extracellular domain of HBS antigens (amino acids 104–120, amino acids 121–137, amino acids 139–148 and amino acids 149–163, Operon Biotechnologies) as antigens.

Immunization of mice and cell preparation. Mouse experiments were approved by the Committee on Animal Experiments at the University of Toyama. We prepared splenocytes from BALB/c mice (Sankyo Labo) immunized with HEL and then isolated CD138+ cells with mouse CD138-specific mAb–conjugated microbeads using autoMACS Separator (Miltenyi Biotec).

Vaccination of human volunteers and cell preparation. Human experiments were performed with the approval of the Ethical Committee at the University of Toyama. We obtained informed consent from all subjects. For HBs antigen–specific antibodies, we immunized healthy volunteers with recombinant adsorbed hepatitis B vaccine (Bimmugen, Kaketsuken) about a year after the three-injection cycle of primary vaccination was completed. For influenza viruses, we inoculated the subjects with influenza 2007–2008 hemagglutinin vaccine (H1N1 A/Solomon Islands/3/2006, H3N2 A/Hiroshima/52/2005 and B/Malaysia/2506/2004). Seven to ten days after the final boost, we transfected both the heavy and light chain expression vectors together into CHO cells to obtain a supernatant containing whole molecules of antibody, as described previously. We examined the antibody specificity of the recombinant antibodies by ELISA and confirmed the results with competitive ELISA by adding soluble antigen together with antibodies. In this study, we screened only IgG-secreting cells with ISAAC and produced IgG.

Enzyme-linked immunosorbent spot assay. We screened 96-well filter plates (MultiScreen, Millipore) with 10 µg ml−1 HEL and blocked them with culture medium. Then, we added mouse CD138+ cells to each well and incubated for 36 h at 37 °C. After washing, we added alkaline phosphatase–conjugated mouse IgG-specific antibody. After washing, we added a mixture of 3-bromo-4-chloro-3-indolyl phosphate toluidine and p-nitroblue tetrazolium chloride (Sigma) to detect immunospots. As a negative control, we used HBs antigen.

Microarray analysis of virus-neutralizing activity for antibodies. We amplified antibody cDNAs for Vγ1 and Vδ fragments using a single-cell 5′-RACE method with primers for γ chain, κ chain and λ chains and inserted them into expression vectors that contained the whole constant region cDNA for heavy or light chains. Thereafter, we transfected both the heavy and light chain expression vectors together into CHO cells to obtain a supernatant containing whole molecules of antibody, as described previously. We then obtained the antigen specificity of the recombinant antibodies by ELISA and confirmed the results with competitive ELISA by adding soluble antigen together with antibodies. In this study, we screened only IgG-secreting cells with ISAAC and produced IgG.

Assay of virus-neutralizing activity for antibodies. We investigated neutralizing activity for hepatitis B virus using HepaRG cells (supplied from BIOPREDICT) and for influenza virus using a previously described protocol with slight modifications (Supplementary Methods).

Supplementary Methods

